Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMINA-1 study of REGN2477 in fibrodysplasia ossificans progressiva
NL-OMON50623Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing REGN2477 with Placebo to REGN2477 (2 arms). Started Apr 2018; status: active, not recruiting.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NL-OMON50623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50623.